Coya Therapeutics (NASDAQ:COYA) Issues Earnings Results

Coya Therapeutics (NASDAQ:COYA) issued its earnings results on Wednesday. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.15, Zacks reports.

Coya Therapeutics Trading Down 0.1 %

Shares of NASDAQ:COYA traded down $0.01 during trading on Friday, hitting $7.21. 48,778 shares of the stock were exchanged, compared to its average volume of 71,559. The company has a market cap of $109.74 million, a PE ratio of -11.09 and a beta of 0.46. Coya Therapeutics has a 12-month low of $4.40 and a 12-month high of $10.69. The company has a fifty day moving average price of $7.02 and a two-hundred day moving average price of $7.05.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. HC Wainwright assumed coverage on Coya Therapeutics in a report on Monday, September 16th. They set a “buy” rating and a $18.00 price objective on the stock. Chardan Capital restated a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research report on Thursday.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.